Chicago, Ill. (PRWEB) March 29, 2010
New tools are now available on http://www.letstalkibs.com to help patients living with irritable bowel syndrome (IBS) describe their symptoms to a healthcare provider and establish an effective treatment plan. IBS is a disorder characterized by symptoms including abdominal pain and discomfort, bloating, and changes in bowel habits such as constipation and/or diarrhea. While this condition affects nearly 1 in 5 Americans, many patients are uncomfortable talking about their IBS symptoms, making it challenging for healthcare providers to properly diagnose and treat patients.
In an effort to bridge this communication gap, letstalkibs.com is offering tools to help patients put their symptoms into words for a more constructive conversation with their healthcare providers. One such tool – a “Describe How You Feel” tool – enables patients to better identify and describe the way they are feeling by using images to represent symptoms of IBS.
“It is important for patients to have an open and honest conversation with their healthcare provider about their IBS symptoms. Once healthcare providers understand a patient’s symptoms and how they may impact daily life, including work productivity, social and physical activities and travel plans, they can better diagnose and treat each individual,” said Dr. Lauren Gerson, M.D., associate professor of medicine & gastroenterology, Stanford University School of Medicine. “The tools available on letstalkibs.com can help patients communicate their IBS symptoms more effectively, and enable them to take control of their health and get the help and support they need.”
For more information and tips about IBS, visit http://www.letstalkibs.com.
Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about these Takeda companies, visit http://www.tpna.com.
Multimedia Release: Multimedia Content Attached
To view the full multimedia news release, please visit http://www.starttalkingibs.com.